<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39938640</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5786</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Actas urologicas espanolas</Title><ISOAbbreviation>Actas Urol Esp (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>NSAIDs: An alternative to antibiotics for infections urinary in women? - An evidence-based review.</ArticleTitle><Pagination><StartPage>501684</StartPage><MedlinePgn>501684</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acuroe.2025.501684</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5786(25)00008-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Urinary tract infections (UTIs) remain a major cause of morbidity in otherwise healthy women. It is estimated at least 50% of women will have at least 1 UTI in their lifetime. Current guidelines recommend the use of antibiotics (ABs) for treatment, constituting the 2nd most common reason for their prescribing. However, antibiotic resistance remains a worrying problem, therefore it is almost imperative to find alternatives for UTIs. One of the most suggested alternatives are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Some clinical trials have shown that these are similar to ABs in resolving urinary symptoms OBJETIVOS: evaluar la eficacia de los AINE en el tratamiento de las ITU no complicadas en mujeres sanas no embarazadas, y demostrar su no inferioridad frente al tratamiento antibi&#xf3;tico. M&#xe9;TODOS: Esta revisi&#xf3;n basada en la evidencia incluy&#xf3; art&#xed;culos publicados entre enero de 2010 y diciembre de 2021 en bases de datos m&#xe9;dicas, utilizando las palabras clave MeSH: &#xab;NSAIDs&#xbb;, &#xab;UTI&#xbb; y &#xab;Treatment&#xbb;. Se utiliz&#xf3; la escala Strength of Recommendation Taxonomy (SORT) para clasificar el nivel de la evidencia.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">De los 8 art&#xed;culos seleccionados, la mayor&#xed;a concluyeron que los AB son m&#xe1;s eficaces para el tratamiento de las ITU, ya que el cuadro cl&#xed;nico se resolvi&#xf3; con mayor rapidez. Sin embargo, seg&#xfa;n los art&#xed;culos, los AINE tambi&#xe9;n demostraron ser eficaces. Por otra parte, se encontr&#xf3; que el tratamiento con AINE no presenta un riesgo mayor de complicaciones.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Los AB siguen siendo el tratamiento de elecci&#xf3;n para las ITU, y a&#xfa;n no hay datos suficientes que apoyen el uso de AINE. Sin embargo, se necesitan m&#xe1;s estudios para evaluar su eficacia en el manejo de los s&#xed;ntomas de las ITU, pues podr&#xed;an suponer una alternativa para reducir la prescripci&#xf3;n de AB.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 AEU. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milhazes Martins</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Unidad de Salud Familiar Flor de Sal, Aveiro, Portugal. Electronic address: milhazes.im17@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dias Batista</LastName><ForeName>S C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Unidad de Salud Familiar Salinas, Cacia, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Urol Esp (Engl Ed)</MedlineTA><NlmUniqueID>101771154</NlmUniqueID><ISSNLinking>2173-5786</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014552" MajorTopicYN="Y">Urinary Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="Y">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AINE</Keyword><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">Antibi&#xf3;ticos</Keyword><Keyword MajorTopicYN="N">ITU</Keyword><Keyword MajorTopicYN="N">NSAIDs</Keyword><Keyword MajorTopicYN="N">Tratamiento</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword><Keyword MajorTopicYN="N">UTIs</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>4</Day><Hour>15</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>13</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>12</Day><Hour>19</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39938640</ArticleId><ArticleId IdType="doi">10.1016/j.acuroe.2025.501684</ArticleId><ArticleId IdType="pii">S2173-5786(25)00008-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38653492</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Rectovaginal Fistula: What Is the Role of Martius Flap and Gracilis Muscle Interposition in the Therapeutic Strategy?</ArticleTitle><Pagination><StartPage>1056</StartPage><EndPage>1064</EndPage><MedlinePgn>1056-1064</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003148</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although numerous treatments exist for the management of rectovaginal fistula, none has demonstrated its superiority. The role of diverting stoma remains controversial. A few series include Martius flap in the armamentarium.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Determine the role of gracilis muscle interposition and Martius flap in the surgical management of rectovaginal fistula.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study of a pooled prospectively maintained database from 3 centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All consecutive eligible patients with rectovaginal fistula undergoing Martius flap and gracilis muscle interposition were included from 2001 to 2022.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Success was defined by the absence of stoma and rectovaginal fistula.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-two patients were included with 55 Martius flap and 24 gracilis muscle interposition performed after failures of 164 initial procedures. Total length of stay was longer for gracilis muscle interposition by 2 days ( p = 0.01) without a significant difference in severe morbidity (20% vs 12%, p = 0.53). Twenty-seven percent of the Martius flap interpositions were performed without a stoma, which did not have an impact on overall morbidity ( p = 0.763). Per patient immediate success rates were not significantly different between groups (35% vs 31%, p &gt; 0.99). The success of gracilis muscle interposition after the failure of the Martius flap was not significantly different from an initial gracilis muscle interposition ( p &gt; 0.99). After simple perineal procedures, the immediate success rate rose to 49.4% (49% vs 50%, p &gt; 0.99). After a median follow-up of 23 months, no significant difference was detected in success rate between the 2 procedures (69% vs 69%, p &gt; 0.99). Smoking was the only negative predictive factor ( p = 0.02).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">By its retrospective nature, this study is limited in its comparison.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This novel comparison between Martius flap and gracilis muscle interposition suggests that Martius flap presents several advantages, including shorter length of stay, similar morbidity, and similar success rate. Proximal diversion via a stoma for Martius flap does not appear mandatory. Gracilis muscle interposition could be reserved as a salvage procedure after Martius flap failure. See Video Abstract .</AbstractText><AbstractText Label="FSTULA RECTOVAGINAL CUL ES EL ROL DEL COLGAJO DE MARTIUS Y LA INTERPOSICIN DEL MSCULO GRACILIS EN LA ESTRATEGIA TERAPUTICA" NlmCategory="UNASSIGNED">ANTECEDENTES:Si bien existen numerosos tratamientos para el manejo de la fistula rectovaginal, ninguno ha demostrado su superioridad. El papel del estoma de derivaci&#xf3;n sigue siendo controvertido. Pocas series incluyen colgajo de Martius en el armamento.OBJETIVO:Determinar el rol de la interposici&#xf3;n del m&#xfa;sculo gracilis y del colgajo de Martius, en el manejo quir&#xfa;rgico de la f&#xed;stula rectovaginal.DISE&#xd1;O:Estudio de cohorte retrospectivo de una base de datos mantenida prospectivamente en 3 centros.AJUSTES/PACIENTES:Se incluyeron todos los pacientes elegibles consecutivos con fistula rectovaginal sometidos a colgajo de Martius y la interposici&#xf3;n del m&#xfa;sculo gracilis desde 2001 hasta 2022.RESULTADOS PRINCIPALES:El &#xe9;xito se defini&#xf3; por la ausencia de estoma y fistula rectovaginal.RESULTADOS:Se incluyeron 62 pacientes con 55 colgajo de Martius y 24 con interposici&#xf3;n del m&#xfa;sculo gracilis realizados despu&#xe9;s de fracasos de 164 procedimientos iniciales. La duraci&#xf3;n total de la estancia hospitalaria fue dos d&#xed;as m&#xe1;s larga para la interposici&#xf3;n del m&#xfa;sculo gracilis ( p = 0,01) sin una diferencia significativa en la morbilidad grave (20% frente a 12%, p = 0,53). El 27% de los colgajos de Martius se realizaron sin estoma, sin impacto en la morbilidad global ( p = 0,763). Las tasas de &#xe9;xito inmediato por paciente no fueron significativamente diferentes entre los grupos (35% vs. 31%, p = 1,0). El &#xe9;xito de la interposici&#xf3;n del m&#xfa;sculo gracilis despu&#xe9;s del fracaso del colgajo de Martius no fue significativamente diferente de una interposici&#xf3;n del m&#xfa;sculo gracilis inicial (p = 1,0). La tasa de &#xe9;xito inmediato aument&#xf3; al 49,4% (49% frente a 50%, p = 1,0) despu&#xe9;s de procedimientos perineales simples. Despu&#xe9;s de una mediana de seguimiento de 23 meses, no se detectaron diferencias significativas en la tasa de &#xe9;xito entre los dos procedimientos (69 % frente a 69 %, p = 1,0). El tabaquismo fue el &#xfa;nico factor predictivo negativo ( p = 0,02).LIMITACIONES:Por su naturaleza retrospectiva, este estudio tiene limitaciones en su comparaci&#xf3;n.CONCLUSI&#xd3;N:Esta novedosa comparaci&#xf3;n entre colgajo de Martius y la interposici&#xf3;n del m&#xfa;sculo gracilis sugiere que el colgajo de Martius presenta varias ventajas, incluida una estancia prolongada m&#xe1;s corta, una morbilidad similar y un &#xe9;xito. La derivaci&#xf3;n proximal a trav&#xe9;s de un estoma para el colgajo de Martius no parece obligatoria. La interposici&#xf3;n del m&#xfa;sculo gracilis podr&#xed;a reservarse como procedimiento de rescate despu&#xe9;s de una falla de colgajo de Martius. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pastier</LastName><ForeName>Cl&#xe9;ment</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loriau</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Visceral Surgery, Groupe Hospitalier Saint Joseph, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denost</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Clinique Tivoli-Ducos, Bordeaux Colorectal Institute, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Lauren V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Centre for Colorectal Disease, St. Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Challine</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collard</LastName><ForeName>Maxime K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debove</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chafai</LastName><ForeName>Najim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parc</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefevre</LastName><ForeName>J&#xe9;r&#xe9;mie H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Sorbonne Universit&#xe9;, AP-HP, H&#xf4;pital Saint Antoine, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071976" MajorTopicYN="Y">Gracilis Muscle</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013524" MajorTopicYN="Y">Surgical Flaps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012006" MajorTopicYN="Y">Rectovaginal Fistula</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064171" MajorTopicYN="N">Superficial Back Muscles</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="N">Plastic Surgery Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054047" MajorTopicYN="N">Surgical Stomas</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38653492</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003148</ArticleId><ArticleId IdType="pii">00003453-202408000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dawes AJ, Jensen CC. Rectovaginal fistulas secondary to obstetrical injury. Clin Colon Rectal Surg. 2021;34:28&#x2013;39.</Citation></Reference><Reference><Citation>Venkatesh KS, Ramanujam PS, Larson DM, Haywood MA. Anorectal complications of vaginal delivery. Dis Colon Rectum. 1989;32:1039&#x2013;1041.</Citation></Reference><Reference><Citation>Lefevre JH, Bretagnol F, Maggiori L, Alves A, Ferron M, Panis Y. Operative results and quality of life after gracilis muscle transposition for recurrent rectovaginal fistula. Dis Colon Rectum. 2009;52:1290&#x2013;1295.</Citation></Reference><Reference><Citation>Faucheron JL, Saint-Marc O, Guibert L, Parc R. Long-term seton drainage for high anal fistulas in Crohn&#x2019;s disease&#x2014;a L operation? Dis Colon Rectum. 1996;39:208&#x2013;211.</Citation></Reference><Reference><Citation>Chirica M, Parc Y, Tiret E, Dehni N, McNamara D, Parc R. Coloanal sleeve anastomosis (Soave procedure): the ultimate treatment option for complex rectourinary fistulas. Dis Colon Rectum. 2006;49:1379&#x2013;1383.</Citation></Reference><Reference><Citation>Meyer J, Ris F, Parkes M, Davies J. Rectovaginal fistula in Crohn&#x2019;s disease: when and how to operate? Clin Colon Rectal Surg. 2022;35:10&#x2013;20.</Citation></Reference><Reference><Citation>Pinto RA, Peterson TV, Shawki S, Davila GW, Wexner SD. Are there predictors of outcome following rectovaginal fistula repair? Dis Colon Rectum. 2010;53:1240&#x2013;1247.</Citation></Reference><Reference><Citation>Corte H, Maggiori L, Treton X, Lefevre JH, Ferron M, Panis Y. Rectovaginal fistula: what is the optimal strategy?: an analysis of 79 patients undergoing 286 procedures. Ann Surg. 2015;262:855&#x2013;860.</Citation></Reference><Reference><Citation>Gottgens KW, Smeets RR, Stassen LP, Beets G, Breukink SO. The disappointing quality of published studies on operative techniques for rectovaginal fistulas: a blueprint for a prospective multi-institutional study. Dis Colon Rectum. 2014;57:888&#x2013;898.</Citation></Reference><Reference><Citation>Maspero M, Otero Pineiro A, Steele SR, Hull TL. Gracilis muscle interposition for the treatment of rectovaginal fistula: a systematic review and pooled analysis. Dis Colon Rectum. 2023;66:631&#x2013;645.</Citation></Reference><Reference><Citation>Venara A, Trilling B, Ngoma M, et al. Ano-rectovaginal fistula after obstetrical anal sphincter injury: diverting stoma does not improve the surgical results. Colorectal Dis. 2022;24:1371&#x2013;1378.</Citation></Reference><Reference><Citation>Zheng H, Guo T, Wu Y, et al. Rectovaginal fistula after low anterior resection in Chinese patients with colorectal cancer. Oncotarget. 2017;8:73123&#x2013;73132.</Citation></Reference><Reference><Citation>Rex JC Jr, Khubchandani IT. Rectovaginal fistula: complication of low anterior resection. Dis Colon Rectum. 1992;35:354&#x2013;356.</Citation></Reference><Reference><Citation>Trompetto M, Realis Luc A, Novelli E, Tutino R, Clerico G, Gallo G. Use of the Martius advancement flap for low rectovaginal fistulas. Colorectal Dis. 2019;21:1421&#x2013;1428.</Citation></Reference><Reference><Citation>Grott M, Rickert A, Hetjens S, Kienle P. Clinical outcome and quality of life after gracilis muscle transposition for fistula closure over a 10-year period. Int J Colorectal Dis. 2021;36:569&#x2013;580.</Citation></Reference><Reference><Citation>Frontali A, Rottoli M, Chierici A, Poggioli G, Panis Y. Rectovaginal fistula: risk factors for failure after graciloplasty&#x2014;a bicentric retrospective European study of 61 patients. Colorectal Dis. 2021;23:2113&#x2013;2118.</Citation></Reference><Reference><Citation>Hull TL, Sapci I, Lightner AL. Gracilis flap repair for reoperative rectovaginal fistula. Dis Colon Rectum. 2023;66:113&#x2013;117.</Citation></Reference><Reference><Citation>Tracanelli L, Mathieu N, Trilling B, Vergniol J, Pigot F, Faucheron JL. Rectovaginal fistula in Crohn&#x2019;s disease treatment: a low long-term success rate and a high definitive stoma risk after a conservative surgical approach. Tech Coloproctol. 2021;25:1143&#x2013;1149.</Citation></Reference><Reference><Citation>Pitel S, Lefevre JH, Parc Y, Chafai N, Shields C, Tiret E. Martius advancement flap for low rectovaginal fistula: short- and long-term results. Colorectal Dis. 2011;13:e112&#x2013;e115.</Citation></Reference><Reference><Citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205&#x2013;213.</Citation></Reference><Reference><Citation>Garoufalia Z, Gefen R, Emile SH, et al. Gracilis muscle interposition for complex perineal fistulas: a systematic review and meta-analysis of the literature. Colorectal Dis. 2023;25:549&#x2013;561.</Citation></Reference><Reference><Citation>Vogel JD, Johnson EK, Morris AM, et al. Clinical practice guideline for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2016;59:1117&#x2013;1133.</Citation></Reference><Reference><Citation>Gaertner WB, Burgess PL, Davids JS, et al.; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2022;65:964&#x2013;985.</Citation></Reference><Reference><Citation>White AJ, Buchsbaum HJ, Blythe JG, Lifshitz S. Use of the bulbocavernosus muscle (Martius procedure) for repair of radiation-induced rectovaginal fistulas. Obstet Gynecol. 1982;60:114&#x2013;118.</Citation></Reference><Reference><Citation>Songne K, Scotte M, Lubrano J, et al. Treatment of anovaginal or rectovaginal fistulas with modified Martius graft. Colorectal Dis. 2007;9:653&#x2013;656.</Citation></Reference><Reference><Citation>McNevin MS, Lee PY, Bax TW. Martius flap: an adjunct for repair of complex, low rectovaginal fistula. Am J Surg. 2007;193:597&#x2013;599.</Citation></Reference><Reference><Citation>Cui L, Chen D, Chen W, Jiang H. Interposition of vital bulbocavernosus graft in the treatment of both simple and recurrent rectovaginal fistulas. Int J Colorectal Dis. 2009;24:1255&#x2013;1259.</Citation></Reference><Reference><Citation>Milito G, Lisi G, Venditti D, Campanelli M, Aronadio E, Grande M. Surgical treatment of rectovaginal fistula in Crohn&#x2019;s disease: a tertiary center experience. Surg Technol Int. 2017;30:113&#x2013;116.</Citation></Reference><Reference><Citation>Kajohnwongsatit K. Single incision modified Martius flap for rectovaginal fistula. Tech Coloproctol. 2021;25:1091&#x2013;1092.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38060955</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1606-7916</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><PubDate><Year>2023</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Salud publica de Mexico</Title><ISOAbbreviation>Salud Publica Mex</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>s7</StartPage><EndPage>s14</EndPage><MedlinePgn>s7-s14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21149/14804</ELocationID><Abstract><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Describir las caracter&#xed;sticas sociodemogr&#xe1;ficas de la poblaci&#xf3;n mexicana, y el acceso a los programas sociales alimentarios de la Encuesta Nacional de Salud y Nutrici&#xf3;n Continua 2022 (Ensanut Continua 2022). Material y m&#xe9;todos. Se presenta la informaci&#xf3;n descriptiva de las caracter&#xed;sticas sociodemogr&#xe1;ficas y de programas sociales de 10 465 hogares de la Ensanut Continua 2022.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">El 96.0% de la poblaci&#xf3;n de 6 a 14 a&#xf1;os y 50% de 15 a 24 asisten a la escuela. Los estudios predominantes en los mayores de 25 a&#xf1;os son de primaria y secundaria (25.0 y 28.7%, respectivamente). El 4.9% de los hogares no tiene agua entubada y 1.2% no tiene drenaje, 1.7% tiene piso de tierra y 0.8% no cuenta con energ&#xed;a el&#xe9;ctrica. El 43.5% de los hogares recibe alg&#xfa;n programa social. Los de mayor cobertura son el Programa de Adultos Mayores (80.5%) y el Programa Nacional de Becas para el Bienestar Benito Ju&#xe1;rez (20.5%).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Este manuscrito permiti&#xf3; describir el contexto de la muestra poblacional que incluy&#xf3; la Ensanut Continua 2022, lo que permite contextualizar los diferentes an&#xe1;lisis que se realicen con esta informaci&#xf3;n y observar su contribuci&#xf3;n en el marco de los determinantes sociales de la salud.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales-Ru&#xe1;n</LastName><ForeName>Mar&#xed;a Del Carmen</ForeName><Initials>MDC</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Evaluaci&#xf3;n y Encuestas, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. cmruan@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayorga-Borbolla</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Evaluaci&#xf3;n y Encuestas, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. ciee35@insp.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arango-Angarita</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Evaluaci&#xf3;n y Encuestas, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. andreaarango20@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe9;ndez-G&#xf3;mez-Humaran</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Matem&#xe1;ticas, A.C. Aguascalientes, M&#xe9;xico.. imendez@cimat.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizuet-Vega</LastName><ForeName>Norma Isela</ForeName><Initials>NI</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Evaluaci&#xf3;n y Encuestas, Instituto Nacional de Salud P&#xfa;blica. Cuernavaca, Morelos, M&#xe9;xico.. ciee17@insp.mx.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Caracter&#xed;sticas sociodemogr&#xe1;ficas de hogares y poblaci&#xf3;n de la Encuesta Nacional de Salud y Nutrici&#xf3;n Continua 2022.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Salud Publica Mex</MedlineTA><NlmUniqueID>0404371</NlmUniqueID><ISSNLinking>0036-3634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38060955</ArticleId><ArticleId IdType="doi">10.21149/14804</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27731538</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0705</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</Title><ISOAbbreviation>Ultrasound Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Single-dose systemic methotrexate vs expectant management for&#x2009;treatment&#x2009;of&#x2009;tubal&#x2009;ectopic&#x2009;pregnancy:&#x2009;a&#x2009;placebo-controlled randomized trial.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>176</EndPage><MedlinePgn>171-176</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/uog.17329</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Methotrexate is used routinely worldwide for the medical treatment of clinically stable women with a tubal ectopic pregnancy. This is despite the lack of robust evidence to show its superior effectiveness over expectant management. The aim of our multicenter randomized controlled trial was to compare success rates of methotrexate against placebo for the conservative treatment of tubal ectopic pregnancy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study took place in two early-pregnancy units in the UK between August 2005 and June 2014. Inclusion criteria were clinically stable women with a conclusive ultrasound diagnosis of a tubal ectopic pregnancy, presenting with a low serum beta human chorionic gonadotropin (&#x3b2;-hCG) level of&#x2009;&lt;&#x2009;1500&#x2009;IU/L. Women were assigned randomly to a single systemic injection of either 50&#x2009;mg/m<sup>2</sup> methotrexate or placebo. The primary outcome was a binary indicator for success of conservative management, defined as resolution of clinical symptoms and decline of serum &#x3b2;-hCG to&#x2009;&lt;&#x2009;20&#x2009;IU/L or a negative urine pregnancy test without the need for any additional medical intervention. An intention-to-treat analysis was followed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We recruited a total of 80 women, 42 of whom were assigned to methotrexate and 38 to placebo. The arms of the study were matched in terms of age, ethnicity, obstetric history, pregnancy characteristics and serum levels of &#x3b2;-hCG and progesterone. The rates of success were similar for the two study arms: 83% with methotrexate and 76% with placebo. On univariate analysis, this difference was not statistically significant (&#x3c7;<sup>2</sup> (1 degree of freedom)&#x2009;=&#x2009;0.53; P&#x2009;=&#x2009;0.47). On multivariate logistic regression, the serum level of &#x3b2;-hCG was the only covariate found to be significantly associated with outcome. The odds of failure increased by 0.15% for each unit increase in &#x3b2;-hCG (odds ratio, 1.0015 (95% CI, 1.0002-1.003); P&#x2009;=&#x2009;0.02). In 14 women presenting with serum &#x3b2;-hCG of 1000-1500&#x2009;IU/L, the success rate was 33% in those managed expectantly compared with 62% in those receiving methotrexate. This difference was not statistically significant and a larger sample size would be needed to give sufficient power to detect a difference in the subgroup of women with higher &#x3b2;-hCG. In women with successful conservative treatment, there was no significant difference in median &#x3b2;-hCG resolution times between study arms (17.5 (interquartile range (IQR), 14-28.0) days (n&#x2009;=&#x2009;30) in the methotrexate group vs 14 (IQR, 7-29.5) days (n&#x2009;=&#x2009;25) in the placebo group; P&#x2009;=&#x2009;0.73).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of our study do not support the routine use of methotrexate for the treatment of clinically stable women diagnosed with tubal ectopic pregnancy presenting with low serum &#x3b2;-hCG (&lt;&#x2009;1500&#x2009;IU/L). Further work is required to identify a subgroup of women with tubal ectopic pregnancy and &#x3b2;-hCG &#x2265;&#x2009;1500&#x2009;IU/L in whom methotrexate may offer a safe and cost-effective alternative to surgery. Copyright &#xa9; 2016 ISUOG. Published by John Wiley &amp; Sons Ltd. Comparaci&#xf3;n entre una sola dosis de metotrexate sist&#xe9;mico y la conducta expectante en el tratamiento de casos de embarazo ect&#xf3;pico tub&#xe1;rico: un ensayo aleatorio controlado con placebo RESUMEN OBJETIVO: El metotrexate se utiliza de modo rutinario en todo el mundo para el tratamiento de las mujeres cl&#xed;nicamente estables con un embarazo ect&#xf3;pico tub&#xe1;rico. Esto sucede a pesar de la falta de evidencia rigurosa que demuestre que su eficacia es superior a la conducta expectante. El objetivo de este ensayo controlado aleatorio multic&#xe9;ntrico fue comparar las tasas de &#xe9;xito del metotrexate con las de un placebo para el tratamiento cauteloso del embarazo ect&#xf3;pico tub&#xe1;rico. M&#xc9;TODOS: Este estudio se llev&#xf3; a cabo en dos cl&#xed;nicas de control de gestaci&#xf3;n temprana en el Reino Unido entre agosto de 2005 y junio de 2014. Los criterios de inclusi&#xf3;n fueron mujeres cl&#xed;nicamente estables con un diagn&#xf3;stico ecogr&#xe1;fico concluyente de embarazo ect&#xf3;pico tub&#xe1;rico, las cu&#xe1;les presentaban una concentraci&#xf3;n s&#xe9;rica baja de la &#x3b2; hormona cori&#xf3;nica gonadotr&#xf3;pica (&#x3b2;-hCG) inferior a 1500 UI/L. Las mujeres fueron asignadas aleatoriamente a una sola inyecci&#xf3;n sist&#xe9;mica de 50&#x2009;mg/m2 de metotrexate o a placebo. El resultado primario fue un indicador binario del &#xe9;xito del tratamiento conservador, definido como la resoluci&#xf3;n de los s&#xed;ntomas cl&#xed;nicos y la disminuci&#xf3;n en el suero de la &#x3b2;-hCG a &lt;20 UI/L o una prueba de embarazo negativa en orina sin la necesidad de ninguna intervenci&#xf3;n m&#xe9;dica adicional. Se hizo un an&#xe1;lisis por intenci&#xf3;n de tratar.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se reclut&#xf3; un total de 80 mujeres; a 42 de ellas se les asign&#xf3; el metotrexate y a 38 el placebo. Los grupos del estudio se realizaron en funci&#xf3;n de la edad, el origen &#xe9;tnico, los antecedentes obst&#xe9;tricos, las caracter&#xed;sticas del embarazo y los niveles s&#xe9;ricos de la &#x3b2;-hCG y la progesterona. Las tasas de &#xe9;xito fueron similares para los dos grupos de estudio: 83% con metotrexate y 76% con placebo. En el an&#xe1;lisis univariante, esta diferencia no fue estad&#xed;sticamente significativa (&#x3c7;2 (1 grado de libertad)&#x2009;=&#x2009;0,53; P = 0,47). En la regresi&#xf3;n log&#xed;stica multivariante, el nivel s&#xe9;rico de la &#x3b2;-hCG fue la &#xfa;nica covariable que se encontr&#xf3; significativamente asociada con el resultado. Las probabilidades de fracaso aumentaron en un 0,15% por cada unidad de aumento de la &#x3b2;-hCG (cociente de probabilidad 1,0015 (IC 95%, 1,0002-1,003); P = 0,02). La tasa de &#xe9;xito en las 14 mujeres con un nivel s&#xe9;rico de la &#x3b2;-hCG de 1000-1500 UI/L fue del 33% en las tratadas con conducta expectante frente al 62% en las que recibieron metotrexate. Esta diferencia no fue estad&#xed;sticamente significativa, por lo que se necesitar&#xed;a un tama&#xf1;o de muestra mayor, lo suficiente como para poder detectar diferencias en el subgrupo de mujeres con una &#x3b2;-hCG m&#xe1;s elevada. En las mujeres en las que el tratamiento conservador tuvo &#xe9;xito, no hubo una diferencia significativa en la mediana de los tiempos de resoluci&#xf3;n de la &#xdf;-hCG entre los grupos del estudio (17,5 (amplitud intercuart&#xed;lica (IQR), 14-28,0) d&#xed;as (n = 30) en el grupo de metotrexate frente a 14 (IQR, 7-29.5) d&#xed;as (n = 25) en el grupo de placebo; P = 0,73).</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="CONCLUSIONS">Los resultados de este estudio no apoyan el uso rutinario de metotrexate para el tratamiento de las mujeres cl&#xed;nicamente estables diagnosticadas con un embarazo ect&#xf3;pico tub&#xe1;rico que presenta un nivel s&#xe9;rico bajo la &#x3b2;-hCG (&lt;1500 UI/L). Ser&#xe1;n necesarios estudios adicionales para identificar un subgrupo de mujeres con embarazo ect&#xf3;pico tub&#xe1;rico y &#x3b2;-hCG &#x2265;1500 UI/L para quienes el metotrexate puede ofrecer una alternativa segura y rentable en comparaci&#xf3;n con la cirug&#xed;a. : : ,,&#x3002;&#x3002; : 2005820146,2&#x3002;,,&#x3b2;(beta human chorionic gonadotropin,&#x3b2;-hCG)&lt;1500 IU/L&#x3002;,(50 mg/m<sup>2</sup> )&#x3002;,&#x3b2;-hCG&lt;20 IU/L,&#x3002;&#x3002; : 80,42,38&#x3002;2&#x3001;&#x3001;&#x3001;&#x3b2;-hCG&#x3002;2:83%,76%&#x3002;,[&#x3c7;<sup>2</sup> (1)=0.53;P=0.47]&#x3002;logistic,&#x3b2;-hCG&#x3002;&#x3b2;-hCG,0.15%[,1.0015(95% CI,1.0002~1.003);P=0.02]&#x3002;14&#x3b2;-hCG1000~1500 IU/L,33%,62%&#x3002;,&#x3b2;-hCG&#x3002;,2&#x3b2;-hCG(P=0.73),17.5[(interquartile range,IQR),14~28.0](n=30),14 (IQR,7~29.5)(n=25)&#x3002; : &#x3001;&#x3001;&#x3b2;-hCG(&lt;1500 IU/L)&#x3002;,&#x3b2;-hCG&gt;1500 IU/L&#x3001;&#x3002;.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 ISUOG. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jurkovic</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Memtsa</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawyer</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donaldson</LastName><ForeName>A N A</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Applied Mathematics &amp; Statistics Department, State University of New York, Stony Brook, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamil</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schramm</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sana</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otify</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farahani</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>N</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1801-6281</Identifier><AffiliationInfo><Affiliation>Institute for Women's Health, University College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambler</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Statistical Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Early Pregnancy Unit, Department of Obstetrics and Gynaecology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ultrasound Obstet Gynecol</MedlineTA><NlmUniqueID>9108340</NlmUniqueID><ISSNLinking>0960-7692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018997">Chorionic Gonadotropin, beta Subunit, Human</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018997" MajorTopicYN="N">Chorionic Gonadotropin, beta Subunit, Human</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011274" MajorTopicYN="N">Pregnancy, Tubal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">expectant</Keyword><Keyword MajorTopicYN="N">methotrexate</Keyword><Keyword MajorTopicYN="N">placebo</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword><Keyword MajorTopicYN="N">treatment</Keyword><Keyword MajorTopicYN="N">tubal ectopic pregnancy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27731538</ArticleId><ArticleId IdType="doi">10.1002/uog.17329</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>